|
|
Article: Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: case studies
- Article from:
- Progress in Transplantation
- Article date:
- June 1, 2006
- Author:
CopyrightCopyright North American Transplant Coordinators Organization Jun 2006. Provided by ProQuest LLC. (Hide copyright information)
|
Background-The potential benefit of the current mycophenolic acid, mycophenolate mofetil, has not yet been fully achieved in clinical transplantation because of its gastrointestinal side effects. Dose splitting, dose reduction, and drug discontinuation are strategies that are used to manage gastrointestinal symptoms. However, recently reported registry data suggest these alterations result in inadequate graft protection, leading to increased late acute rejection rates and decreased long-term graft survival.
Objective-To investigate the potential use of the new enteric-coated formulation of mycophenolic acid therapy, mycophenolate sodium, and its suggested improved side effects profile.
...